Breast Cancer

Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer

July 07, 2020

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

Sacituzumab Govitecan Demonstrates Further Survival Efficacy in mTNBC

July 06, 2020

"The results of the global phase 3 ASCENT study confirm our initial observations that sacituzumab govitecan has the potential to change the standard management of mTNBC."

COVID-19 Death Toll in NYC Calls Attention to Racial Disparities

July 02, 2020

In New York City, high cases of COVID-19 continue to be reported with a high prevalence among racial and ethnic minorities.

Combination Immunotherapy Appears Promising in Breast Cancer Subtypes

June 25, 2020

Sylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.

Investigating How to Help Patients With Breast Cancer Stay on Therapy

June 25, 2020

Julie Gralow, MD, discusses the use of patient-reported outcomes in the SWOG S1105 trial and different factors for patients with early-stage breast cancer on an aromatase inhibitor to see if they could predict who may be more likely to stop taking treatment early.

Atezolizumab Plus Chemotherapy Improves Responses in Triple-Negative Breast Cancer

June 18, 2020

IMpassion031, a clinical trial of atezolizumab plus chemotherapy in patients with triple-negative breast cancer, has met its primary end point.

MonarchE Meets Primary End Point with Abemaciclib Combo in HR+, HER2- Breast Cancer

June 16, 2020

"We can potentially offer a new treatment option for patients with high-risk HR-positive, HER2-negative early breast cancer. "

Veliparib Combination Induces Significant Improvement in PFS for BRCA-Like Advanced TNBC

June 03, 2020

“With demonstration of efficacy in biomarker-selected BRCA-like phenotype triple-negative breast cancer, the results of this trial are a very positive step toward expanding the role of PARP inhibitors beyond germline BRCA in breast cancer."

Pembrolizumab Plus Chemotherapy Show Efficacy for TNBC in KEYNOTE-355

June 03, 2020

Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.

Palbociclib Expected to Miss Its Mark in HR+, HER2– Breast Cancer

June 01, 2020

"We are disappointed [with] this outcome. Breast cancer is a leading cause of death around the world and delaying or preventing the development of metastatic disease is a significant unmet need. PALLAS is a large study with many subgroups and we are actively collaborating to determine if there are patients who may benefit from adjuvant treatment with the palbociclib combination."